Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study.
Lavanya RamanIain D StewartShaney Louise BarrattFelix ChuaNazia ChaudhuriAnjali CrawshawMichael GibbonsCharlotte HogbenRachel HoylesVasilis KouranosJennifer MartinovicSarah MulhollandKatherine J MyallMarium NaqviElisabetta A RenzoniPeter SaundersMatthew S StewardDharmic SureshMuhunthan ThillaiAthol U WellsAlex G WestJane A MitchellPeter M GeorgePublished in: ERJ open research (2023)
In PPF, the real-world efficacy of nintedanib replicated that of clinical trials, significantly attenuating lung function decline. Despite the severity of disease, nintedanib was safe and well tolerated in this real-world multicentre study.
Keyphrases
- idiopathic pulmonary fibrosis
- lung function
- clinical trial
- pulmonary fibrosis
- interstitial lung disease
- cystic fibrosis
- chronic obstructive pulmonary disease
- air pollution
- multiple sclerosis
- study protocol
- rheumatoid arthritis
- systemic sclerosis
- electronic health record
- cross sectional
- phase ii
- randomized controlled trial
- big data
- open label
- double blind
- artificial intelligence
- deep learning
- data analysis